ECS Botanics announces UK distribution and manufacturing agreement with Curaleaf Laboratories
ECS Botanics Holdings told the ASX on 7 October 2026 it has entered a distribution and manufacturing agreement with Curaleaf Laboratories for ECS-branded medicinal cannabis in the UK.
Market Disclosure — price-sensitive ASX announcement by ECS Botanics Holdings Ltd (ACN 009 805 298)
ECS Botanics Holdings Ltd (ASX: ECS) told the ASX on 7 October 2026 that it has entered a distribution and manufacturing agreement with Curaleaf Laboratories (Rokshaw Limited) covering ECS-branded medicinal cannabis products in the United Kingdom.
According to the announcement, ECS will supply bulk dried flower and Curaleaf Laboratories will carry out local manufacturing and distribution. The company said it keeps ownership of the product until it is sold, and that the start of supply depends on regulatory approvals.
The announcement states the agreement has an initial two-year term with automatic renewal, and that either party may end it after the first anniversary on three months' notice. It also states the agreement contains no minimum purchase commitments and that ECS has not provided revenue projections.
The company described the agreement as following its earlier entry into the German market. Managing director Nan-Maree Schoerie said it "represents another important step in ECS's international growth strategy".
This summary reports what the company announced to the market. The terms of the agreement have not been independently verified.
Source: ASX — ECS Botanics Holdings Ltd, "ECS Launches UK Branded Portfolio with Curaleaf" (published 7 October 2026)